Diovan recalled for failing dissolution specifications — the right ingredient still has to dissolve

1Having the active ingredient is not enough

The quality of a tablet is not settled by containing the right ingredient in the right amount. A tablet only works once it dissolves in the digestive tract and releases its active ingredient. Too slow and blood concentration does not rise; too fast and behavior departs from what was intended. A dissolution test measures that rate under specified conditions. This recall follows a failure to meet that specification.

2An uncommon type of reason

Only 9 of the 1,408 records this site holds as of 2026-09-02 cite failed dissolution. Set against 353 for sterility and microbial contamination or 109 for undeclared allergens, it is a type one rarely encounters — because it is not visible from outside like contamination or a mislabel, and surfaces only through a prescribed test.

3The character of the drug involved

Valsartan is an antihypertensive taken on a continuing basis. What follows from dissolution behavior outside specification depends on the formulation and the patient, but the concern is that the intended blood concentration may not be reached. That the classification is Class II rather than Class I reflects the assessment of likelihood and seriousness of harm. Among the records this site holds, Class II accounts for the large majority at 1,089.

4The two-layer structure of contract manufacturing

Here Novartis distributes the product while Patheon manufactures it. In pharmaceuticals, distributor and manufacturer are frequently different companies, and recall records name both. Which stage produced the quality problem is not recoverable from the record, but this two-layer structure is the premise for thinking about where responsibility and corrective action sit.

If you are taking the product, do not stop on your own judgment; follow healthcare professionals and the official information from the FDA and the manufacturer.